UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

The New England journal of medicine, 2013-09, Vol.369 (11), p.999-1010

2013

Volltextzugriff (PDF)

Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes: Results of the SWAP (Switching Anti Platelet) Study

Journal of the American College of Cardiology, 2010-09, Vol.56 (13), p.1017-1023

2010

Volltextzugriff (PDF)

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study

Thrombosis and haemostasis, 2013, Vol.109 (2), p.347-355

2013

Volltextzugriff (PDF)

Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry

Critical care (London, England), 2010-01, Vol.14 (3), p.R102-R102, Article R102

2010

Volltextzugriff (PDF)

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

Thrombosis and haemostasis, 2013-12, Vol.110 (6), p.1223-1231

2013

Volltextzugriff (PDF)

Cardiovascular Safety Update of Tadalafil: Retrospective Analysis of Data from Placebo-Controlled and Open-Label Clinical Trials of Tadalafil With As Needed, Three Times-per-Week or Once-a-Day Dosing

The American journal of cardiology, 2006-06, Vol.97 (12), p.1778-1784

2006

Volltextzugriff (PDF)

Drotrecogin alfa (activated) in severe sepsis

The Lancet infectious diseases, 2013-02, Vol.13 (2), p.108-109

2013

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Diabetes therapy, 2017-06, Vol.8 (3), p.545-554

2017

Volltextzugriff (PDF)

Update on Clinical Trials of Tadalafil Demonstrates No Increased Risk of Cardiovascular Adverse Events

Journal of sexual medicine, 2004-09, Vol.1 (2), p.161-167

2004

Volltextzugriff (PDF)

Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel: Results from PRINCIPLE-TIMI 44

Thrombosis and haemostasis, 2011-08, Vol.106 (8), p.219-226

2011

Volltextzugriff (PDF)

Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes

Journal of the American College of Cardiology, 2010-09, Vol.56 (13), p.1017-1023

2010

Volltextzugriff (PDF)

The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT Interval

Journal of the American College of Cardiology, 2005-08, Vol.46 (4), p.678-687

2005

Volltextzugriff (PDF)

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Current medical research and opinion, 2014-11, Vol.30 (11), p.2193-2205

2014

Volltextzugriff (PDF)

Effects of tadalafil on myocardial blood flow in patients with coronary artery disease

Coronary artery disease, 2006-09, Vol.17 (6), p.493-499

2006

Volltextzugriff (PDF)

Efficacy and Safety of On‐Demand Oral Tadalafil in the Treatment of Men with Erectile Dysfunction in Taiwan: A Randomized, Double‐Blind, Parallel, Placebo‐Controlled Clinical Study

Journal of sexual medicine, 2004-09, Vol.1 (2), p.201-208

2004

Volltextzugriff (PDF)

Retinal effects of 6 months of daily use of tadalafil or sildenafil

Archives of ophthalmology (1960), 2009-04, Vol.127 (4), p.367

2009

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus^sup ^ Insulin Glargine

Diabetes therapy, 2017-06, Vol.8 (3), p.545

2017

Volltextzugriff (PDF)

Abstract 9871: Enhanced Active Metabolite Generation and Platelet Inhibition With Prasugrel Compared to Clopidogrel Regardless of Genotype in Thienopyridine Metabolic Pathways

Circulation (New York, N.Y.), 2012-11, Vol.126 (suppl_21)

2012

Volltextzugriff (PDF)

Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44

Thrombosis and haemostasis, 2011-08, Vol.106 (2), p.219

2011

Volltextzugriff (PDF)

Abstract 4948: Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) Study

Circulation (New York, N.Y.), 2009-11, Vol.120 (suppl_18)

2009

Volltextzugriff (PDF)

Optimal second-order product probability bounds

Journal of applied probability, 1993-09, Vol.30 (3), p.675-691

1993

Volltextzugriff (PDF)

1170-147 Effect of tadalafil, a phosphodiesterase 5 inhibitor, on myocardial blood flow in patients with coronary artery disease

Journal of the American College of Cardiology, 2004-03, Vol.43 (5), p.A369-A369

2004

Volltextzugriff (PDF)

The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. Commentary

Journal of the American College of Cardiology, 2005, Vol.46 (4), p.678-689

2005

Volltextzugriff (PDF)

Combination setwise-Bonferroni-type bounds

Naval research logistics, 1996-02, Vol.43 (1), p.59-77

Costigan, Timothy M.

1996

Volltextzugriff (PDF)

Optimal second-order product probability bounds

Journal of applied probability, 1993-09, Vol.30 (3), p.675-691

1993

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(36)
Dissertationen
(1)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Male
(16)
Middle Aged
(14)
Aged
(13)
Female
(11)
Biological And Medical Sciences
(10)
Adult
(9)
Medical Sciences
(9)
Double-Blind Method
(8)
Piperazines - Administration & Dosage
(7)
Tadalafil
(7)
Cardiology
(6)
Cardiovascular System & Cardiology
(6)
Prasugrel Hydrochloride
(6)
Carbolines - Adverse Effects
(5)
Cardiology. Vascular System
(5)
Clopidogrel
(5)
Drug Therapy
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes

Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes: Results of the SWAP (Switching Anti Platelet) Study

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study

Global utilization of low-dose corticosteroids in severe sepsis and septic shock: a report from the PROGRESS registry

Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways

Cardiovascular Safety Update of Tadalafil: Retrospective Analysis of Data from Placebo-Controlled and Open-Label Clinical Trials of Tadalafil With As Needed, Three Times-per-Week or Once-a-Day Dosing

Drotrecogin alfa (activated) in severe sepsis

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine

Update on Clinical Trials of Tadalafil Demonstrates No Increased Risk of Cardiovascular Adverse Events

Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel: Results from PRINCIPLE-TIMI 44

Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes

The Combined Use of Ibutilide as an Active Control With Intensive Electrocardiographic Sampling and Signal Averaging as a Sensitive Method to Assess the Effects of Tadalafil on the Human QT Interval

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Effects of tadalafil on myocardial blood flow in patients with coronary artery disease

Efficacy and Safety of On‐Demand Oral Tadalafil in the Treatment of Men with Erectile Dysfunction in Taiwan: A Randomized, Double‐Blind, Parallel, Placebo‐Controlled Clinical Study

Retinal effects of 6 months of daily use of tadalafil or sildenafil

Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus^sup ^ Insulin Glargine

Abstract 9871: Enhanced Active Metabolite Generation and Platelet Inhibition With Prasugrel Compared to Clopidogrel Regardless of Genotype in Thienopyridine Metabolic Pathways

Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44

Abstract 4948: Decrease in Poor Responders on Switching From Clopidogrel to Prasugrel: Results From the SWitching Anti Platelet (SWAP) Study

Optimal second-order product probability bounds

1170-147 Effect of tadalafil, a phosphodiesterase 5 inhibitor, on myocardial blood flow in patients with coronary artery disease

The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. Commentary

Combination setwise-Bonferroni-type bounds

Optimal second-order product probability bounds

Suchergebnisse filtern